The association of neurofibromatosis, bilateral pheochromocytoma and primary hyperparathyroidism

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 7, 2007, Pages 468-470

  Altinova, A E ^a,b   Toruner, F ^a   Cimen, A R ^a   Karakoc, A ^a   Atasever, T ^a   Yetkin, I ^a   Ayvaz, G ^a   Cakir, N ^a   Arslan, M ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Hyperparathyroidism; Neurofibromatosis; Parathyroid adenoma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; GLUCOCORTICOID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MINERALOCORTICOID; PHOSPHORUS;

ADRENALECTOMY; ADULT; ARTICLE; BONE DENSITY; CAFE AU LAIT SPOT; CALCIUM BLOOD LEVEL; CASE REPORT; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; MALE; NEUROFIBROMATOSIS; PARATHYROID ADENOMA; PHEOCHROMOCYTOMA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SYMPTOM; URINALYSIS;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADULT; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; NEUROFIBROMATOSES; PARATHYROID NEOPLASMS; PHEOCHROMOCYTOMA;

EID: 34547799197     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981661     Document Type: Article

References (26)

1. Abdel-Wanis ME, Kawahara N, Tomita K. The association of neurofibromatosis 1 and spinal deformity with primary hyperparathyroidism and osteomalacia: might melatonin have a role? J Orthop Sci 2001; 6: 193-198
2. Al-Wahhabi B. Parathyroid adenoma and bilateral pheochromocytoma in a patient with neurofibromatosis. Ann Saudi Med 2005; 25: 255-257
3. Benn DE, Dwight T, Richardson AL, Delbridge L, Bambach CP, Stowasser M, Gordon RD, Marsh DJ, Robinson BG. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Res 2000; 60: 7048-7051
4. Chakrabarti S, Murugesan A, Arida EJ. The association of neurofibromatosis and hyperparathyroidism. Am J Surg 1979; 137: 417-420
5. Daly D, Kaye M, Estrada RL. Neurofibromatosis and hyperparathyroidism-a new syndrome? Can Med Assoc J 1970; 103: 258-259
6. Freimanis MG, Rodgers RW, Samaan NA. Neurofibromatosis and primary hyperparathyroidism. South Med J 1984; 77: 794-795
7. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70: 138-143
8. Gimm O. Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. Fam Cancer 2005; 4: 17-23
9. Giorgetti PL, Pizzocari P, De Monti M, Rampoldi V, Rignano A, Vandone PL, Miani S. Association of pheochromocytoma and phakomatosis. Apropos of a clinical case. Minerva Chir 1991; 46: 479-488
10. Goldberg Y, Dibbern K, Klein J, Riccardi VM, Graham Jr JM. Neurofibromatosis type 1-an update and review for the primary pediatrician. Clin Pediatr (Phila) 1996; 35: 545-561
11. Hernandez FC, Sanchez M, Alvarez A, Diaz J, Pascual R, Perez M, Tovar I, Martinez P. A five-year report on experience in the detection of pheochromocytoma. Clin Biochem 2000; 33: 649-655
12. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005; 37: 717-721
13. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 2005; 16: 928-936
14. Learoyd DL, Marsh DJ, Richardson AL, Twigg SM, Delbridge L, Robinson BG. Genetic testing for familial cancer. Consequences of RET protooncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch Surg 1997; 132: 1022-1025
15. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet 2005; 366: 665-675
16. Moiton MP, Bijou F, Vargas F, Valentino R, Gruson D, Hilbert G, Benissan G, Cardinaud JP. Association of type 1 neurofibromatosis and primary hyperparathyroidism. Presse Med 2002; 31: 1604-1605
17. Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 2005; 4: 13-16
18. Patocs A, Karadi E, Toth M, Varga I, Szucs N, Batogh K, Majnik J, Glaz E, Racz K. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev 2004; 13: 403-409
19. Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes. F Ann Endocrinol 2005; 66: 178-185
20. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis. Am J Epidemiol 2000; 151: 33-40
21. Schimke RN, Hartmann WH, Prout TE, Rimoin DL. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med 1968; 279: 1-7
22. Segni M, Massa R, Bonifacio V, Tartaglia F, Pucarelli I, Marzullo A, Pasquino AM. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1. Horm Res 2001; 56: 63-66
23. Syed Z, Khan A. Skeletal effects of primary hyperparathyroidism. Endocr Pract 2000; 6: 385-388
24. Vogelzang PJ, Oates E, Bankoff MS. Parathyroid adenoma associated with neurofibromatosis: correlative scintigraphic and magnetic resonance imaging. Clin Nucl Med 1989; 14: 168-170
25. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. Von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 62: 582-586
26. Yohay K. Neurofibromatosis types 1 and 2. Neurologist 2006; 12: 86-93